1. Home
  2. BROS vs TGTX Comparison

BROS vs TGTX Comparison

Compare BROS & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dutch Bros Inc.

BROS

Dutch Bros Inc.

N/A

Current Price

$35.58

Market Cap

8.5B

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$64.33

Market Cap

8.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
BROS
TGTX
Founded
1992
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.5B
8.5B
IPO Year
2021
2008

Fundamental Metrics

Financial Performance
Metric
BROS
TGTX
Price
$35.58
$64.33
Analyst Decision
Strong Buy
Buy
Analyst Count
27
7
Target Price
$55.04
★ $77.50
AVG Volume (30 Days)
★ 5.1M
1.9M
Earning Date
11-04-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
88.24
★ 1746.67
EPS
★ 0.60
0.52
Revenue
★ $1,638,159,000.00
$2,785,000.00
Revenue This Year
$29.79
$61.95
Revenue Next Year
$24.60
$35.55
P/E Ratio
★ $56.01
$124.76
Revenue Growth
★ 27.88
N/A
52 Week Low
$33.17
$26.76
52 Week High
$74.02
$68.03

Technical Indicators

Market Signals
Indicator
BROS
TGTX
Relative Strength Index (RSI) 39.38 64.72
Support Level $33.17 $51.70
Resistance Level $44.78 N/A
Average True Range (ATR) 1.90 3.49
MACD -0.71 0.65
Stochastic Oscillator 19.65 73.78

Price Performance

Historical Comparison
BROS
TGTX

About BROS Dutch Bros Inc.

Dutch Bros Inc is an operator and franchisor of drive-thru coffee shops that are focused on serving hand-crafted beverages. The company's hand-crafted beverage-focused lineup features hot and cold espresso-based beverages, cold brew coffee products, proprietary energy drinks, tea, lemonade, smoothies, and other beverages. The company has two reportable operating segments Company-operated shops and Franchising. It derives maximum revenue from Company-operated shops.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: